Retraction of “Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy”

The Editors retract this Article due to concerns about the reliability and reproducibility of the published data. Concerns have been raised surrounding the Sorafenib cancer treatment model. Additionally, the Article does not contain appropriate experimental details to allow for reproduction of the results. These concerns are significant enough to cast doubts on the main findings of the work.

The original Article was published on September 2, 2020, and retracted on July 19, 2021.